The combination of PD-L1 expression and decreased tumorinfiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer

Hitomi Mori, Makoto Kubo, Rin Yamaguchi, Reiki Nishimura, Tomofumi Osako, Nobuyuki Arima, Yasuhiro Okumura, Masayuki Okido, Mai Yamada, Masaya Kai, Junji Kishimoto, Yoshinao Oda, Masafumi Nakamura

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

This study included patients with primary triple-negative breast cancer (TNBC) who underwent resection without neoadjuvant chemotherapy between January 2004 and December 2014. Among the 248 TNBCs studied, programmed cell death ligand-1 (PD-L1) expression was detected in 103 (41.5%) tumors, and high levels of tumor-infiltrating lymphocytes (TILs) were present in 118 (47.6%) tumors. PDL1 expression correlated with high levels of TILs, but was not a prognostic factor. Patients with TILs-high tumors had better overall survival than those with TILslow tumors (P = 0.016). There was a strong interaction between PD-L1 expression and TILs that was associated with both recurrence-free survival (P = 0.0018) and overall survival (P = 0.015). Multivariate Cox proportional hazards model analysis showed that PD-L1-positive/TILs-low was an independent negative prognostic factor for both recurrence-free survival and overall survival. Our findings suggest that PDL1- positive/TILs-low tumors are associated with a poor prognosis in patients with TNBC, and that it is important to focus on the combination of PD-L1 expression on tumor cells and TILs present in the tumor microenvironment. These biomarkers may be useful for stratification of TNBCs and for predicting prognosis and developing novel cancer immunotherapies.

Original languageEnglish
Pages (from-to)15584-15592
Number of pages9
JournalOncotarget
Volume8
Issue number9
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Triple Negative Breast Neoplasms
Tumor-Infiltrating Lymphocytes
Cell Death
Lymphocytes
Ligands
Survival
Neoplasms
Recurrence
Tumor Microenvironment
Proportional Hazards Models
Immunotherapy
Biomarkers
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

The combination of PD-L1 expression and decreased tumorinfiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. / Mori, Hitomi; Kubo, Makoto; Yamaguchi, Rin; Nishimura, Reiki; Osako, Tomofumi; Arima, Nobuyuki; Okumura, Yasuhiro; Okido, Masayuki; Yamada, Mai; Kai, Masaya; Kishimoto, Junji; Oda, Yoshinao; Nakamura, Masafumi.

In: Oncotarget, Vol. 8, No. 9, 01.01.2017, p. 15584-15592.

Research output: Contribution to journalArticle

Mori, Hitomi ; Kubo, Makoto ; Yamaguchi, Rin ; Nishimura, Reiki ; Osako, Tomofumi ; Arima, Nobuyuki ; Okumura, Yasuhiro ; Okido, Masayuki ; Yamada, Mai ; Kai, Masaya ; Kishimoto, Junji ; Oda, Yoshinao ; Nakamura, Masafumi. / The combination of PD-L1 expression and decreased tumorinfiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. In: Oncotarget. 2017 ; Vol. 8, No. 9. pp. 15584-15592.
@article{4e7c2e52c01f46cba66dbb8c9827b9da,
title = "The combination of PD-L1 expression and decreased tumorinfiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer",
abstract = "This study included patients with primary triple-negative breast cancer (TNBC) who underwent resection without neoadjuvant chemotherapy between January 2004 and December 2014. Among the 248 TNBCs studied, programmed cell death ligand-1 (PD-L1) expression was detected in 103 (41.5{\%}) tumors, and high levels of tumor-infiltrating lymphocytes (TILs) were present in 118 (47.6{\%}) tumors. PDL1 expression correlated with high levels of TILs, but was not a prognostic factor. Patients with TILs-high tumors had better overall survival than those with TILslow tumors (P = 0.016). There was a strong interaction between PD-L1 expression and TILs that was associated with both recurrence-free survival (P = 0.0018) and overall survival (P = 0.015). Multivariate Cox proportional hazards model analysis showed that PD-L1-positive/TILs-low was an independent negative prognostic factor for both recurrence-free survival and overall survival. Our findings suggest that PDL1- positive/TILs-low tumors are associated with a poor prognosis in patients with TNBC, and that it is important to focus on the combination of PD-L1 expression on tumor cells and TILs present in the tumor microenvironment. These biomarkers may be useful for stratification of TNBCs and for predicting prognosis and developing novel cancer immunotherapies.",
author = "Hitomi Mori and Makoto Kubo and Rin Yamaguchi and Reiki Nishimura and Tomofumi Osako and Nobuyuki Arima and Yasuhiro Okumura and Masayuki Okido and Mai Yamada and Masaya Kai and Junji Kishimoto and Yoshinao Oda and Masafumi Nakamura",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14698",
language = "English",
volume = "8",
pages = "15584--15592",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "9",

}

TY - JOUR

T1 - The combination of PD-L1 expression and decreased tumorinfiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer

AU - Mori, Hitomi

AU - Kubo, Makoto

AU - Yamaguchi, Rin

AU - Nishimura, Reiki

AU - Osako, Tomofumi

AU - Arima, Nobuyuki

AU - Okumura, Yasuhiro

AU - Okido, Masayuki

AU - Yamada, Mai

AU - Kai, Masaya

AU - Kishimoto, Junji

AU - Oda, Yoshinao

AU - Nakamura, Masafumi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - This study included patients with primary triple-negative breast cancer (TNBC) who underwent resection without neoadjuvant chemotherapy between January 2004 and December 2014. Among the 248 TNBCs studied, programmed cell death ligand-1 (PD-L1) expression was detected in 103 (41.5%) tumors, and high levels of tumor-infiltrating lymphocytes (TILs) were present in 118 (47.6%) tumors. PDL1 expression correlated with high levels of TILs, but was not a prognostic factor. Patients with TILs-high tumors had better overall survival than those with TILslow tumors (P = 0.016). There was a strong interaction between PD-L1 expression and TILs that was associated with both recurrence-free survival (P = 0.0018) and overall survival (P = 0.015). Multivariate Cox proportional hazards model analysis showed that PD-L1-positive/TILs-low was an independent negative prognostic factor for both recurrence-free survival and overall survival. Our findings suggest that PDL1- positive/TILs-low tumors are associated with a poor prognosis in patients with TNBC, and that it is important to focus on the combination of PD-L1 expression on tumor cells and TILs present in the tumor microenvironment. These biomarkers may be useful for stratification of TNBCs and for predicting prognosis and developing novel cancer immunotherapies.

AB - This study included patients with primary triple-negative breast cancer (TNBC) who underwent resection without neoadjuvant chemotherapy between January 2004 and December 2014. Among the 248 TNBCs studied, programmed cell death ligand-1 (PD-L1) expression was detected in 103 (41.5%) tumors, and high levels of tumor-infiltrating lymphocytes (TILs) were present in 118 (47.6%) tumors. PDL1 expression correlated with high levels of TILs, but was not a prognostic factor. Patients with TILs-high tumors had better overall survival than those with TILslow tumors (P = 0.016). There was a strong interaction between PD-L1 expression and TILs that was associated with both recurrence-free survival (P = 0.0018) and overall survival (P = 0.015). Multivariate Cox proportional hazards model analysis showed that PD-L1-positive/TILs-low was an independent negative prognostic factor for both recurrence-free survival and overall survival. Our findings suggest that PDL1- positive/TILs-low tumors are associated with a poor prognosis in patients with TNBC, and that it is important to focus on the combination of PD-L1 expression on tumor cells and TILs present in the tumor microenvironment. These biomarkers may be useful for stratification of TNBCs and for predicting prognosis and developing novel cancer immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=85014122863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014122863&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14698

DO - 10.18632/oncotarget.14698

M3 - Article

C2 - 28107186

AN - SCOPUS:85014122863

VL - 8

SP - 15584

EP - 15592

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 9

ER -